AREV Brands International Ltd. (OTCQB: AREVF) (CSE: AREV) is pleased to announce that its common shares have been approved for trading on the OTCQB Market (“OTCQB”) under the symbol “AREVF” effective as of the open of trading today, October 9, 2019.
“The listing of our common stock on the OTCQB Market is a long awaited and welcome milestone for AREV Brands International,” comments Mike Withrow, CEO of AREV. “Since building our asset base we have been very proactive and focused on upgrade to the OTCQB and will uplist our shares again as we meet the U.S. exchange requirements by growing our business and market capitalization. We believe that the broader exposure afforded by the OTCQB will raise our visibility within the investment community and assist in increasing the liquidity of our common stock. In addition, we believe that trading on this established public market will help to generate exposure of our Company among institutional and foreign investors.”
The OTCQB is a venture market operated by OTC Markets Group and designed for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. To learn more, visit otcmarkets.com.
For further information, contact Mike Withrow, mike@AREVBrands.com 778-379-8551.
On behalf of the Board,
Mike Withrow CEO & Director
About AREV Brands International Ltd.
AREV Brands International Ltd. (“AREV”) produces and delivers functional compounds and ingredients from its worldclass extraction systems. AREV is revolutionizing the current delivery method of terpenes, cannabinoids and flavonoids. These premium ingredients and formulations are used in products targeted for sale in the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV innovates through extraction to produce extracts from specific selected plant and exude from trees that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.